SK19495A3 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
SK19495A3
SK19495A3 SK194-95A SK19495A SK19495A3 SK 19495 A3 SK19495 A3 SK 19495A3 SK 19495 A SK19495 A SK 19495A SK 19495 A3 SK19495 A3 SK 19495A3
Authority
SK
Slovakia
Prior art keywords
benzylidene
piperazinedione
compound
methyl
dimethyl
Prior art date
Application number
SK194-95A
Other languages
English (en)
Slovak (sk)
Inventor
Mark A D Collins
Maria I Chicarelli-Robinson
Justin S Bryans
Christopher J Latham
Stephen J Brocchini
Original Assignee
Xenova Limited British Body Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Limited British Body Co filed Critical Xenova Limited British Body Co
Publication of SK19495A3 publication Critical patent/SK19495A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK194-95A 1992-08-14 1993-08-16 Pharmaceutical compositions SK19495A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929217331A GB9217331D0 (en) 1992-08-14 1992-08-14 Pharmaceutical compounds
PCT/GB1993/001735 WO1994004513A1 (en) 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines

Publications (1)

Publication Number Publication Date
SK19495A3 true SK19495A3 (en) 1995-11-08

Family

ID=10720385

Family Applications (2)

Application Number Title Priority Date Filing Date
SK194-95A SK19495A3 (en) 1992-08-14 1993-08-16 Pharmaceutical compositions
SK195-95A SK19595A3 (en) 1992-08-14 1993-08-16 Diketopiperazines, method of their preparation, use and pharmaceutical agent which containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK195-95A SK19595A3 (en) 1992-08-14 1993-08-16 Diketopiperazines, method of their preparation, use and pharmaceutical agent which containing them

Country Status (24)

Country Link
US (1) US5700804A (hu)
EP (2) EP0672036A1 (hu)
JP (2) JPH08504175A (hu)
KR (2) KR950702967A (hu)
AT (1) ATE162186T1 (hu)
AU (2) AU693420B2 (hu)
BG (2) BG99496A (hu)
BR (2) BR9306905A (hu)
CA (2) CA2141938A1 (hu)
CZ (2) CZ38195A3 (hu)
DE (1) DE69316370T2 (hu)
DK (1) DK0655060T3 (hu)
ES (1) ES2111169T3 (hu)
FI (2) FI950617A (hu)
GB (2) GB9217331D0 (hu)
GR (1) GR3026272T3 (hu)
HU (2) HUT71592A (hu)
IL (2) IL106695A0 (hu)
PL (2) PL307437A1 (hu)
RU (2) RU95108759A (hu)
SK (2) SK19495A3 (hu)
TW (1) TW334427B (hu)
WO (2) WO1994004512A1 (hu)
ZA (2) ZA935968B (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9402805D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
GB9402809D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9410387D0 (en) * 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
GB9426090D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426071D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB2310854B (en) * 1994-12-23 1998-09-09 Xenova Ltd Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
GB9426224D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB2311781B (en) * 1994-12-23 1998-09-16 Xenova Ltd Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
AU779230C (en) * 1999-12-03 2006-05-25 Emory University Curcumin analogues for treating cancer
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
US6635649B2 (en) * 2000-05-09 2003-10-21 Che-Ming Teng Piperazinedione compounds
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
ES2294026T3 (es) 2000-09-06 2008-04-01 Ap Pharma, Inc. Polimeros degradables de poliacetal.
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6815214B2 (en) * 2000-12-29 2004-11-09 Celltech R & D, Inc. Pharmaceutical uses and synthesis of diketopiperazines
GB2372740A (en) * 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
CA2478522A1 (en) * 2002-03-08 2003-09-18 Emory University Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
PT1529044E (pt) 2002-08-02 2008-01-14 Nereus Pharmaceuticals Inc Desidrofenila-histinas e os seus análogos e a síntese de desidrofenila-histinas e os seus análogos
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DE10238144A1 (de) * 2002-08-15 2004-02-26 Basf Ag Verwendung von Diketopiperazin-Derivaten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
WO2004030522A2 (en) 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
CA2523467C (en) * 2003-05-15 2021-10-26 Dmi Biosciences, Inc. Treatment of t-cell mediated diseases
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
US7732605B2 (en) 2005-03-29 2010-06-08 Nereus Pharmaceuticals, Inc. Synthesis of diketopiperazines
US20070270464A1 (en) * 2006-02-24 2007-11-22 Emory University Prodrugs of curcumin analogs
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
CA2826973C (en) * 2011-02-10 2020-03-24 Mannkind, Corp Formation of n-protected bis-3,6-(4-aminoalkyl)-2,5,diketopiperazine
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
AU2012323305B2 (en) 2011-10-10 2017-07-27 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2012328605B9 (en) 2011-10-28 2017-08-03 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CN103396372B (zh) * 2013-08-09 2015-05-20 中国科学院南海海洋研究所 一类2,5-二酮哌嗪衍生物及其制备方法和在制备抗海洋污损生物防除剂中的应用
CN105272968B (zh) * 2014-06-10 2018-03-13 首都医科大学 (3s,6r)‑3,6二取代哌嗪‑2,5‑二酮,其制备及应用
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN104610170B (zh) * 2015-01-14 2017-02-01 中国科学院南海海洋研究所 2,5‑二酮哌嗪衍生物及其制备方法和应用
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
EP3265090A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating cancer associated with a ras mutation
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
MX2018015100A (es) 2016-06-06 2019-09-04 Beyondspring Pharmaceuticals Inc Composicion y metodo para reducir la neutropenia.
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US11129878B1 (en) 2020-03-24 2021-09-28 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE621862C (de) * 1932-07-01 1935-11-14 Guenther Schiemann Dr Verfahren zur Darstellung von Kondensationsprodukten kernfluorierter Arylaldehyde
BE584914A (hu) * 1958-11-24
JPS5747357A (en) * 1980-09-04 1982-03-18 Ricoh Co Ltd Novel disazo compound and its preparation
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
RU95108759A (ru) 1996-12-10
GB9217331D0 (en) 1992-09-30
ZA935969B (en) 1995-02-16
KR950702968A (ko) 1995-08-23
IL106695A0 (en) 1993-12-08
RU95108387A (ru) 1996-12-10
JPH08504176A (ja) 1996-05-07
SK19595A3 (en) 1995-09-13
FI950617A (fi) 1995-04-13
ES2111169T3 (es) 1998-03-01
ZA935968B (en) 1995-02-16
US5700804A (en) 1997-12-23
DE69316370D1 (de) 1998-02-19
AU693420B2 (en) 1998-07-02
BG99495A (en) 1995-12-29
EP0655060A1 (en) 1995-05-31
FI950616A0 (fi) 1995-02-13
WO1994004513A1 (en) 1994-03-03
EP0655060B1 (en) 1998-01-14
BG99496A (en) 1995-12-29
KR950702967A (ko) 1995-08-23
EP0672036A1 (en) 1995-09-20
CZ38395A3 (en) 1995-10-18
CZ38195A3 (en) 1995-09-13
PL307438A1 (en) 1995-05-29
CA2141939A1 (en) 1994-03-03
GR3026272T3 (en) 1998-06-30
AU4726593A (en) 1994-03-15
HU9500437D0 (en) 1995-04-28
BR9306904A (pt) 1998-12-08
GB2284420B (en) 1996-09-25
HU9500436D0 (en) 1995-04-28
IL106696A0 (en) 1993-12-08
TW334427B (en) 1998-06-21
AU678172B2 (en) 1997-05-22
DK0655060T3 (da) 1998-02-09
HUT71592A (en) 1996-01-29
DE69316370T2 (de) 1998-07-16
BR9306905A (pt) 1998-12-08
CA2141938A1 (en) 1994-03-03
JPH08504175A (ja) 1996-05-07
FI950616A (fi) 1995-04-13
PL307437A1 (en) 1995-05-29
GB9502859D0 (en) 1995-04-05
ATE162186T1 (de) 1998-01-15
GB2284420A (en) 1995-06-07
FI950617A0 (fi) 1995-02-13
AU4726493A (en) 1994-03-15
WO1994004512A1 (en) 1994-03-03
HUT71593A (en) 1996-01-29

Similar Documents

Publication Publication Date Title
SK19495A3 (en) Pharmaceutical compositions
JP6228130B2 (ja) 治療活性化合物およびそれらの使用方法
RU2728827C2 (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
US5852018A (en) Pharmaceutical piperazine compounds
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
EP2964223A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2018519249A (ja) イソオキサゾリル置換ベンズイミダゾール類
KR101569261B1 (ko) 암을 치료하기 위한 hdac 억제제로서 4-아미노-n-하이드록시-벤즈아미드
EA022341B1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
WO2003041641A2 (en) Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
TW200815387A (en) Chromen-2-one derivatives
JP2593273B2 (ja) 置換ジアミノフタルイミドおよび同族体
SK83697A3 (en) Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
WO2018005801A2 (en) Novel non-systemic tgr5 agonists
KR20130086608A (ko) 암 치료용 신규 ｎ-하이드록시-벤즈아마이드
KR20230171449A (ko) 브루톤 티로신 키나제 억제제의 공결정질 형태
KR100412167B1 (ko) 다중약물내성의조절제로서의피페라진-2,5-디온유도체
JP5330377B2 (ja) ３，４−ジヒドロキナゾリン誘導体
US20220267289A1 (en) Selective bcrp/abcg2 transporter inhibitors as agents to abolish resistance to anti-cancer agents
US5861400A (en) Pharmaceutical compounds
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
CN115052855A (zh) 酰胺化合物的制备方法、其晶型及其盐类
US20190240244A1 (en) Compounds for cancer chemotherapeutic sensitization
EP4317143A1 (en) Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
SK286055B6 (sk) Indenoindolónové zlúčeniny, spôsob ich prípravy afarmaceutické kompozície s ich obsahom